SCHEMBL19724259

SCHEMBL19724259

Cc1ccc(C(=O)Nc2cc(C=O)ccc2C)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 4/20 0.50
▸ HDAC6 Q9UBN7 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.46
▸ PRKAB2 O43741 1/20 0.45
▸ PRKAG1 P54619 1/20 0.45
▸ PRKAA2 P54646 1/20 0.45
▸ PRKAA1 Q13131 1/20 0.45
▸ PRKAG3 Q9UGI9 1/20 0.45
▸ PRKAG2 Q9UGJ0 1/20 0.45
▸ PRKAB1 Q9Y478 1/20 0.45
▸ HDAC3 O15379 2/20 0.45
▸ HDAC2 Q92769 2/20 0.45
▸ NPC1 O15118 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ MAPK13 O15264 1/20 0.43
▸ MAPK12 P53778 1/20 0.43
▸ MAPK11 Q15759 1/20 0.43
▸ MAPK14 Q16539 1/20 0.43
▸ KCNQ3 O43525 1/20 0.43
▸ KCNQ2 O43526 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15652289 0.78 HPGD (0.61) HDAC1HDAC6KDM4EHDAC3NPC1
SCHEMBL26838909 0.77 POLB (0.63) HDAC1HDAC6KDM4ENPC1RAB9A
SCHEMBL10090803 0.76 MAPK14 (0.70) MAPK13MAPK12MAPK11MAPK14
SCHEMBL5044729 0.75 HDAC1 (0.41) HDAC1HDAC6KDM4ENPC1RAB9A
SCHEMBL29950977 0.74 ALDH1A1 (0.52) NPC1RAB9APOLBLMNASMN1; SMN2
SCHEMBL7215753 0.74 ALDH1A1 (0.52) NPC1RAB9APOLBLMNASMN1; SMN2
SCHEMBL3647392 0.72 RAB9A (0.58) HDAC1KDM4EHDAC3HDAC2NPC1
SCHEMBL15886864 0.71 TUBB1 (0.51) HDAC1HDAC6HDAC3HDAC2HDAC8
SCHEMBL4762998 0.70 NPC1 (0.66) HDAC1HDAC6KDM4EHDAC3HDAC2
SCHEMBL16371435 0.70 KIT (0.61) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3077387-B1 BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER JANSSEN PHARMACEUTICA NV (BE) 2017-12-20 — — EP disclosed
Send feedback